Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH)

被引:0
|
作者
Monti, S
Di Silverio, F
Toscano, V
Martini, C
Lanzara, S
Varasano, PA
Sciarra, F
机构
[1] Univ La Sapienza, Dept Med Pathophysiol, Rome, Italy
[2] Univ La Sapienza, Dept Urol, Rome, Italy
来源
JOURNAL OF ANDROLOGY | 1998年 / 19卷 / 04期
关键词
testosterone; DHT; 3; alpha-androstanediol;
D O I
暂无
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Benign prostatic hyperplasia (BPH) is an androgen-dependent disease that initially develops in the inner prostate, where the highest concentrations of testosterone (T) and dihydrotestosterone (DHT) are found. In this study, we have evaluated the cytosolic androgen receptors (ARc), the nuclear androgen receptors (ARn), and the concentrations of T, DHT, and 3 alpha-androstanediol (3 alpha Diol) in BPH tissue to verify the existence of a possible correlation between androgens and their receptor concentrations. Prostatic samples, removed by suprapubic prostatectomy in 15 untreated patients, were sectioned in periurethral, intermediate, and subcapsular zones. Testosterone, DHT, and 3 alpha Diol were evaluated by radioimmunoassay after extraction and purification on celite microcolumns, and ARc and ARn were evaluated by means of dextran-coated charcoal method. In total tissue, mean levels of DHT, T, and 3 alpha Diol were 2,531 +/- 308, 260 +/- 36, and 403 +/- 35 pg/mg of DNA (mean a SE), respectively. Cytosolic androgen receptors, detectable in all cases, were 16 +/- 2.8 fmol/mg of protein (mean +/- SE), and ARn, detectable in 12 cases, were 108 +/- 15 fmol/mg of DNA (mean +/- SE). A linear correlation between DHT and 3 alpha Diol, T and DHT, and 3 alpha Diol and ARn was found. If the different regions are considered, the periurethral zone, site of the primitive BPH nodule, presents the highest levels of androgens and ARn with respect to the other regions. This relative hyperandrogenism may be responsible for the growth-promoting processes of this area, leading to urinary obstruction.
引用
收藏
页码:428 / 433
页数:6
相关论文
共 45 条
  • [31] Receptors for Luteinizing Hormone-Releasing Hormone (LHRH) in Benign Prostatic Hyperplasia (BPH) as Potential Molecular Targets for Therapy With LHRH Antagonist Cetrorelix
    Bernadett Rozsa
    Nadji, Mehrdad
    Schally, Andrew V.
    Balazs Dezso
    Flasko, Tibor
    Toth, Gyorgy
    Mile, Melinda
    Block, Norman L.
    Halmos, Gabor
    PROSTATE, 2011, 71 (05): : 445 - 452
  • [32] Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer
    van der Sluis, Tim M.
    Meuleman, Eric J. H.
    van Moorselaar, R. Jeroen A.
    Bui, Hong N.
    Blankenstein, Marinus A.
    Heijboer, Annemieke C.
    Vis, Andre N.
    BJU INTERNATIONAL, 2012, 109 (02) : 183 - 188
  • [33] Hormone concentration, metabolic disorders and immunoexpression of androgen and estrogen-alpha receptors in men with benign prostatic hyperplasia and testosterone deficiency syndrome
    Ryl, Aleksandra
    Rotter, Iwona
    Slojewski, Marcin
    Dolegowska, Barbara
    Grabowska, Marta
    Baranowska-Bosiacka, Irena
    Laszczynska, Maria
    FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2015, 53 (03) : 227 - 235
  • [34] Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?
    Choi, J
    Ikeguchi, EF
    Lee, SW
    Choi, HY
    Te, AE
    Kaplan, SA
    EUROPEAN UROLOGY, 2002, 42 (01) : 7 - 11
  • [36] Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
    Cindolo, Luca
    Pirozzi, Luisella
    Sountoulides, Petros
    Fanizza, Caterina
    Romero, Marilena
    Castellan, Pietro
    Antonelli, Alessandro
    Simeone, Claudio
    Tubaro, Andrea
    de Nunzio, Cosimo
    Schips, Luigi
    BMC UROLOGY, 2015, 15
  • [37] Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
    Luca Cindolo
    Luisella Pirozzi
    Petros Sountoulides
    Caterina Fanizza
    Marilena Romero
    Pietro Castellan
    Alessandro Antonelli
    Claudio Simeone
    Andrea Tubaro
    Cosimo de Nunzio
    Luigi Schips
    BMC Urology, 15
  • [38] THE AUTOPSY PREVALENCES OF PROSTATE CANCER, BENIGN PROSTATIC HYPERPLASIA, AND HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA ARE HIGHER AMONG CAUCASIAN MEN IN THE US THAN ASIAN MEN IN ASIA
    Parsons, J. Kellogg
    Magi-Galluzzi, Christina
    Joshu, Cornine
    Fedor, Helen
    Miller, Gary
    Nelson, William
    Platz, Elizabeth
    DeMarzo, Angelo
    JOURNAL OF UROLOGY, 2013, 189 (04): : E141 - E141
  • [39] Serum prostate-specific antigen is a predictor of the transition zone volume rather than total prostate volume in men with benign prostatic hyperplasia.
    Zlotta, Alexandre R.
    Ben Addi, Taoufik
    Schulman, Claude C.
    Rigatti, Patrizio
    Scattoni, Vincenzo
    Montorsi, Francesco
    Fleshner, Neil E.
    Finelli, Antonio
    JOURNAL OF UROLOGY, 2007, 177 (04): : 495 - 496
  • [40] Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp
    Hibberts, NA
    Howell, AE
    Randall, VA
    JOURNAL OF ENDOCRINOLOGY, 1998, 156 (01) : 59 - 65